The Cycle Turns: Why R&D Leaders Are Revisiting Their Custom Synthesis Supply Chain
I. A Shift Underway
If you are a medicinal chemistry or process development lead, you may have sensed some subtle changes over the past few months.
Procurement approvals seem to be moving a bit more smoothly than last year. Expansion projects that were put on hold are being revisited. Supplier inquiry response times have quietly shortened.
These are not illusions. In the first half of 2026, China's pharmaceutical industry has been undergoing a cycle shift—from "capital winter" to "value reassessment." For procurement decision-makers and R&D leads at global drug discovery organizations, the timing to reassess intermediate and custom synthesis suppliers may have arrived.
II. What the Data Says
Consider a few numbers.
In the first half of 2026, the total value of China's innovative drug out-licensing deals reached $99.7 billion to $110 billion. To put this in perspective: that is roughly twice the full-year total of 2024, and 73% of the full-year total of 2025.
Of the global top 10 biopharma BD deals, eight involved Chinese companies. Partners include AstraZeneca, Pfizer, Eli Lilly, and other major multinational pharmaceutical companies. A total of 23 mega-deals exceeded $1 billion each, up 28% year-over-year.
On the capital markets side, as of July 2026, the pharmaceutical sector's PE (TTM) stood at 29x, at the 26th percentile over the past 20 years. Non-pharmaceutical fund holdings in pharma reached just 4.82%—the lowest since 2010. Investment and financing are also rebounding: global healthcare financing in H1 2026 reached RMB 241.6 billion, up 27.7% year-over-year; China's portion reached RMB 67.6 billion, up 65.1%.
Policy signals are also emerging. The 2026 national drug reimbursement list update introduced a "pre-application" mechanism for the first time—innovative drugs that have completed technical review but have not yet received formal marketing approval can now pre-apply for reimbursement listing. Meanwhile, the commercial insurance innovative drug list is now synchronized with the basic reimbursement list application process. A pathway of "commercial insurance first, basic reimbursement follow" is taking shape.
III. What These Changes Mean for R&D Supply Chains
For researchers in the lab, these macro numbers may feel distant. But their ripple effects are gradually becoming visible.
More innovative drugs entering clinical and commercial stages translate into sustained demand for high-purity intermediates, chiral building blocks, and complex heterocyclic compounds. As a drug candidate moves from "target validation" to "clinical supply," and from "clinical" to "commercial preparation"—each stage places different demands on the supply chain: from gram-scale flexibility to kilogram-scale consistency; from rapid delivery to batch-to-batch reproducibility.
More importantly, as more Chinese innovative drug companies become key players in global deal-making, the frequency of collaboration between overseas R&D organizations and Chinese custom synthesis providers is increasing. Not because of cost—though cost advantages remain—but because responsiveness, technical depth, and IP protection awareness have improved significantly.
IV. Beixinke Chem's Perspective and Position
As a custom synthesis service provider based in Shanghai, specializing in inhibitor small molecules, heterocyclic intermediates, and chiral building blocks, Beixinke Chem has witnessed the ups and downs of this cycle firsthand.
We have observed that when the industry is at a low point, R&D organizations tend to scale back external collaborations and compress procurement budgets. When the cycle turns, the first segment to recover is often early-stage R&D custom synthesis—because that is the link in the drug discovery chain that most requires external specialized support.
Our core capabilities cover the entire chain from retrosynthetic analysis to process scale-up: chiral construction, heterocyclic assembly, milligram-to-kilogram scale-up, and full HPLC/LC-MS/NMR analytical support. We have provided custom synthesis support to R&D labs and biotech companies both in China and internationally—across different scales and requirements.
The value reassessment now underway in the industry opens new possibilities—for us and for our clients. Smoother communication, more flexible supply, deeper technical collaboration—things that were compressed during the cycle low are becoming feasible again.
If your R&D team is also exploring supply chain optimization, we would welcome the conversation.